Modern Approaches to the Treatment of Sepsis: Are There New Hopes? (Lecture)

Clinical Microbiology and Antimicrobial Chemotherapy. 2002; 4(4):300-312

​ Cohen J.
Section
Diseases and Pathogens
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2002; 4(4):300-312
  • 1. Goossens H., MYSTIC Study Group (Europe).MYSTIC program: summary of European data from 1997to 2000. Diagn Microbiol Infect Dis 2001; 41:183-9.
  • 2. Resistance ofEnterococcusspp. to antimicrobials(Smolensk). Available from URL: http://www.antibio-tic.ru/en/ar/pub/arrussia.shtml.
  • 3. Ibrahim E.H., Sherman G., Ward S., Fraser V.J., Kol-lef M.H., et al. The influence of inadequate antimicrobialtreatment of bloodstream infections on patient outcomesin the ICU setting. Chest 2000; 118:146-55.
  • 4. Guidelines for the management of severe sepsis and sep-tic shock. The International Sepsis Forum. IntensiveCare Med 2001; 27 (Suppl 1):S1-134.
  • 5. Cometta A., Baumgartner J.D., Lew D., et al. Prospectiverandomized comparison of imipenem monotherapy withimipenem plus netilmicin for treatment of severe infec-tions in nonneutropenic patients. Antimicrob AgentsChemother 1994; 38:1309-13.
  • 6. Solberg C.O., Sjursen H. Safety and efficacy ofmeropenem in patients with septicaemia: a randomisedcomparison with ceftazidime, alone or combined withamikacin. J Antimicrob Chemother 1995; 36 (SupplA):157-66.
  • 7. Mouton Y.J., Beuscart C. Empirical monotherapy withmeropenem in serious bacterial infections. MeropenemStudy Group. J Antimicrob Chemother 1995; 36 (SupplA):145-56.
  • 8. Oblinger M.J., Bowers J.T., Sande M.A., Mandell G.L.Moxalactam therapy versus standard antimicrobial the-rapy for selected serious infections. Rev Infect Dis 1982;4 (Suppl):S639-49.
  • 9. Arich C., Gouby A., Bengler C., et al. [Comparison of theefficacy of cefotaxime alone and the combination cefa-zolin-tobramycin in the treatment of enterobacterial sep-ticemia]. Pathol Biol (Paris) 1987; 35:613-5.
  • 10. Extermann M., Regamey C., Humair L., et al. Initialtreatment of sepsis in non-neutropenic patients: cef-tazidime alone versus «best guess» combined antibiotictherapy. Chemotherapy 1995; 41:306-15.
  • 11. McCormick P.A., Greenslade L., Kibbler C.C., et al.A prospective randomized trial of ceftazidime versusnetilmicin plus mezlocillin in the empirical therapy ofpresumed sepsis in cirrhotic patients. Hepatology 1997;25:833-6.
  • 12. Diekema D.J., Jones R.N. Oxazolidinone antibiotics.Lancet 2001; 358(9297):1975-82.
  • 13. Rubinstein E., Cammarata S., Oliphant T., Wunderink R.,Linezolid Nosocomial Pneumonia Study Group.Linezolid (PNU-100766) versus vancomycin in thetreatment of hospitalized patients with nosocomial pneu-monia: a randomized, double-blind, multicenter study.Clin Infect Dis 2001; 32:402-12.
  • 14. Singh N., Yu V.L. Rational empiric antibiotic prescrip-tion in the ICU. Chest 2000; 117:1496-9.
  • 15. Bollaert P.E., Charpentier C., Levy B., et al. Reversal oflate septic shock with supraphysiologic doses of hydro-cortisone. Crit Care Med 1998; 26:645-50.
  • 16. Annane D., Sebille V., Troche G., et al. A 3-level prognostic classification in septic shock based on cortisollevels and cortisol response to corticotropin. JAMA 2000;283:1038-45.
  • 17. Annane D., Sebille V., Charpentier C., et al. Effect oftreatment with low doses of hydrocortisone and fludro-cortisone on mortality in patients with septic shock.JAMA 2002; 288:862-71.
  • 18. Bernard G.R., Vincent J.L., Laterre P.F., et al.Recombinant human protein C Worldwide Evaluationin Severe Sepsis (PROWESS) study group. Efficacyand safety of recombinant human activated protein Cfor severe sepsis. N Engl J Med 2001; 344(10):699-709.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared